Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer

BACKGROUND: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimuma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Antonia, Scott, Goldberg, Sarah B., Balmanoukian, Ani, Chaft, Jamie E., Sanborn, Rachel E., Gupta, Ashok, Narwal, Rajesh, Steele, Keith, Gu, Yu, Karakunnel, Joyson Joseph, Rizvi, Naiyer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500167/
https://ncbi.nlm.nih.gov/pubmed/26858122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00544-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados